AQT is a usable test for dementia assessments in primary care. Sensitivity for AQT is superior to CDT, equivalent to MMSE, and comparable to the combination MMSE and CDT. MMSE in combination with AQT improves sensitivity. Because AQT is user-friendly and quickly administered, it could be applicable for primary care settings.
AQT – A Quick Test of Cognitive Speed
Improving life for patients with neuropsychiatric diseases through a fast and efficient screening and assessment and an accurate monitoring of the treatment based on objective data.
AQT was twice as sensitive as the MMSE in detecting treatment response to AChEI in patients with AD.
Sebastian Palmquist, PhD, Lund UniversityValidation of brief cognitive tests in mild cognitive impairment, Alzheimer’s disease and dementia with Lewy bodies. Publication/Series: Lund University, Faculty of Medicine Doctoral Dissertation Series. Volume: 2011:64
In conclusion, this test allows, due to the measurement of cognitive processing speed, the detection of cognitive impairment at its very early stages, promoting an early diagnosis of neurodegenerative processes in the aging process.
Judith Subirana, PhD, Universitat Ramon Llull, Barcelona.Valoració del deteriorament cognitiu a través de la velocitat de processament. Adaptació de la prova ‘Quick Test of Cognitive Speed (QTCS)’. Tesis doctoral, Facultat de Psicologia, CIències de l’Educació i de l’Esport Blanquerna – Universitat Ramon Llull.
A Quick Test of Cognitive Speed is an objective, reliable and standardized screening and monitoring tool for the assessment and treatment of Alzheimer’s Disease, Lewy Bodies Dementia and Parkinson’s Disease Dementia.
The test has high sensitivity and can detect cognitive impairment, even at a very early stage.
In contrast to a test like MMSE, AQT has no ceiling and can monitor changes accurately for patients with both mild and severe cognitive impairment.
The name AQT derives from two aspects of the test: That it measures the cognitive speed of fundamental executive functions as attention, working memory, set shifting and cognitive control, and that the 3 tasks of the version of the test for clinical practice can be performed quickly – generally in less than 3 minutes.
AQT measures the processing speed in three rapid automatic naming tasks of color and form: two single-dimension tasks (Color and Form) that measure the processing speed of reaction, retrieval and response, and a dual-dimension task (Color-Form together) that further measures the processing speed of attention, working memory, set-shifting (focusing and reorienting attention) and cognitive control.
AQT results are not influenced by gender, socio-cultural background or years of education after grade 8, and naming times increase minimally with age, about 1 sec. per decade in normal adults.(3)
The test results are highly reliable with test-retest correlations (r) of .91 for color, .92 for form, and .95 for color-form naming and there is no evidence of learning.
AQT – at a glance
- Is quick – can generally be performed in less than 3 minutes.
- Can detect cognitive impairment, even at its very early stages.
- Twice as sensitive as the MMSE in detecting treatment response. (17)
- No ceiling effect – able to monitor changes, even in severe cognitive impairment.
- Test-retest reliable – can be repeated without learning.
- No influence from gender or sociocultural background.
- Validated in English, Spanish, Swedish, Norwegian and Danish, Greek, Italian, Turkish and Arab – with more languages to come.
Neuroimaging shows that the rapid automatic naming of combinations of color and form creates bilateral activation of temporal-parietal and sub-cortical brain regions and hippocampus, regions associated with focusing and reorienting attention, keeping visual items active in working memory, set shifting, and cognitive control.(3)
HOW TO ORDER
AQT will be available for international shipping soon.
You are welcome to register your mail address here, and then we will inform you when the test is available for ordering.
AQT Assessment ApS is a Danish company, but with strong ties to scientific communities in Sweden, Spain, Greece, Italy and USA were many of the clinical studies behind “A Quick Test of Cognitive Speed” have been realized.
It is the mission of the company to help practitioners in their effort to improve life for patients with neuropsychiatric diseases through a fast and efficient screening and assessment and an accurate monitoring of the treatment based on objective data.